

1. Record Nr.	UNINA9910812264703321
Autore	Hausman Melissa <1959->
Titolo	Reproductive rights and the state : getting the birth control, RU-486, morning-after pills, and the Gardasil vaccine to the U.S. market // Melissa Hausman
Pubbl/distr/stampa	Santa Barbara, Calif. : , : Praeger, , c2013 New York : , : Bloomsbury Publishing (US), , 2023
ISBN	979-82-16-00775-3 979-82-16-13863-1 0-313-39823-2
Edizione	[1st ed.]
Descrizione fisica	1 online resource (184 p.)
Collana	Reproductive rights and policy
Disciplina	363.9/60973
Soggetti	Birth control - Government policy - United States Birth control - Law and legislation - United States Contraceptives - United States Reproductive rights - United States Women's rights - United States
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Bibliographic Level Mode of Issuance: Monograph
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	Introduction -- History of the FDA and drug regulation in the US -- The development of the pill -- U.S. pro-choice and pro-life groups' strategies since 1960 -- Problems with Mifepristone (RU 486) and Misoprostol (Cytotec), 1988-2000 -- The "Morning after pill," Plan B levonorgestrel formulation -- Reverse lobbying for Gardasil -- Conclusion--why a feminist historical institutionalist lens is important.
Sommario/riassunto	Reproductive Rights and the State: Getting the Birth Control, RU-486, and Morning-After Pills and the Gardasil Vaccine to the U.S. Market tackles a subject that remains controversial more than 60 years after "the pill" was approved for use in the United States. The first book to examine the politicization of the FDA approval process for reproductive drugs, this study maps the hard-fought battles over the four major drugs currently on the U.S. market. To make her case, Melissa Hausman scrutinizes the history of the FDA and the statutes that have governed it, as well as interactions between the U.S.

government, American pharmaceutical companies, and the medical community. The analysis centers on explaining how three reproductive drugs were kept off the U.S. market well after their efficacy had been proven, while the availability of the fourth, Gardasil, has less to do with helping girls than with preserving the financial wellbeing of Merck. Readers will come away understanding how, when it comes to reproductive drugs, women's health concerns have consistently taken a backseat to political agendas and corporate profits.
